US 11,744,860 B2
Technology for efficient activation of NKT cells
Masaru Taniguchi, Wako (JP); Tomokuni Shigeura, Wako (JP); Minako Aihara, Wako (JP); and Keigo Hanada, Tokyo (JP)
Assigned to RIKEN, Wako (JP); and AMBICION CO., LTD., Tokyo (JP)
Appl. No. 16/96,561
Filed by RIKEN, Wako (JP); and AMBICION CO., LTD., Tokyo (JP)
PCT Filed Apr. 14, 2017, PCT No. PCT/JP2017/015383
§ 371(c)(1), (2) Date Oct. 25, 2018,
PCT Pub. No. WO2017/188033, PCT Pub. Date Nov. 2, 2017.
Claims priority of application No. 2016-091674 (JP), filed on Apr. 28, 2016.
Prior Publication US 2019/0134094 A1, May 9, 2019
Int. Cl. A61K 35/17 (2015.01); A61P 35/00 (2006.01); C12N 5/0783 (2010.01)
CPC A61K 35/17 (2013.01) [A61P 35/00 (2018.01); C12N 5/0646 (2013.01)] 14 Claims
 
1. A method for producing an NKT cell ligand-pulsed human CD14 positive CD1d positive cell, comprising a step of culturing an isolated CD14 positive CD1d positive cell in a serum free medium containing an NKT cell ligand and GM-CSF at a concentration of 33.3-666.7 ng/mL,
wherein the NKT cell ligand is a compound represented by the formula

OG Complex Work Unit Chemistry
or a salt thereof,
a compound represented by the formula

OG Complex Work Unit Chemistry
or a salt thereof,
a compound represented by the formula

OG Complex Work Unit Chemistry
or a salt thereof, or
α GalCer.